Skip to main content
. 2019 Feb 12;51(4):1336–1346. doi: 10.4143/crt.2018.504

Fig. 2.

Fig. 2.

Breast cancer-free interval by LPBC change status in overall population (A, B), luminal A (C), luminal B-HER2– (D), luminal B-HER2+ (E), HER2+ (F), and TNBC (G) patients. LPBC, lymphocyte predominant breast cancer; nLPBC, non-lymphocyte-predominant breast cancer; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.